NMRA Key Statistics, Chart & Performance
The current stock price of NMRA is 2.93 USD. In the past month the price increased by 34.68%. In the past year, price increased by 71.84%.
NMRA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NMRA. When comparing the yearly performance of all stocks, NMRA is one of the better performing stocks in the market, outperforming 90.89% of all stocks.
NMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRA. NMRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NMRA Financial Highlights
Over the last trailing twelve months NMRA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 22.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.88% | ||
| ROE | -178.79% | ||
| Debt/Equity | 0.15 |
NMRA Forecast & Estimates
14 analysts have analysed NMRA and the average price target is 9.33 USD. This implies a price increase of 218.29% is expected in the next year compared to the current price of 2.93.
NMRA Ownership
NMRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.46 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 574.257B | ||
| MRK | MERCK & CO. INC. | 21.94 | 290.769B | ||
| PFE | PFIZER INC | 9.28 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.93 | 123.896B | ||
| ZTS | ZOETIS INC | 18.73 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.62 | 25.52B | ||
| VTRS | VIATRIS INC | 6.32 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.68 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.8 | 9.291B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NMRA
Company Profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Company Info
NEUMORA THERAPEUTICS INC
260 Arsenal Place, Suite 1
Watertown MASSACHUSETTS US
Employees: 95
Phone: 18577600900
NEUMORA THERAPEUTICS INC / NMRA FAQ
What does NMRA do?
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Can you provide the latest stock price for NEUMORA THERAPEUTICS INC?
The current stock price of NMRA is 2.93 USD. The price decreased by -2.01% in the last trading session.
What is the dividend status of NEUMORA THERAPEUTICS INC?
NMRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NMRA stock?
NMRA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting NMRA stock to perform?
14 analysts have analysed NMRA and the average price target is 9.33 USD. This implies a price increase of 218.29% is expected in the next year compared to the current price of 2.93.
Can you provide the sector and industry classification for NEUMORA THERAPEUTICS INC?
NEUMORA THERAPEUTICS INC (NMRA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for NEUMORA THERAPEUTICS INC?
NEUMORA THERAPEUTICS INC (NMRA) will report earnings on 2026-04-27, before the market open.